SARS-CoV-2
Conditions
Keywords
infertility; SARS-CoV-2,COVID-19
Brief summary
Patients going through an in vitro fertilization cycle will be asked to participate . Patients will be asked for their COVID-19 exposure : post confirmed disease/post vaccine/not exposed to disease or vaccine . Patients will provide the fluids which are not required , once fertilization process is completed. Patients will also provide 5ml blood sample by the day of procedure. Anti COVID-19 immunoglobulin G type antibodies will be measured in all samples . Data regarding age, date of infection/vaccine will be collected . Progesterone and Estrogen will be measured in female patients' samples and Perlecan level will be measured in follicular fluid.
Detailed description
Patients going through an in vitro fertilization cycle will be asked to participate . Patients will be asked for their COVID-19 exposure : post confirmed disease/post vaccine/not exposed to disease or vaccine . Patients will provide the fluids which are not required in the day of egg retrieval : the follicular fluid remaining after isolation of the egg and spermatic fluid only, if not utilized for fertilization. The fluids will be collected once fertilization process is completed. Patients will also provide 5ml blood sample by the day of procedure. Anti COVID-19 immunoglobulin G type antibodies will be measured in all samples . Data regarding age, date of infection/vaccine will be collected as well as indication for treatment, Estradiol level before the egg retrieval, number of eggs collected and the triggering ovulation modality . Progesterone and Estrogen will be measured in female patients' samples (follicular fluid and serum). Perlecan level will be measured in follicular fluid.
Interventions
DIAGNOSTIC_TESTAnti COVID19 IgG Antibodies
Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
Sponsors
Meir Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Inclusion criteria
* Planned egg retrieval procedure (including egg preservation) * Negative PCR for SARS-Cov-19 in the week before egg retrival * Informed consent
Exclusion criteria
* Positive PCR for SARS-Cov-19 in the week before egg retrival * expected retrival of 1-3 eggs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Follicular - Serum Anti COVID-19 antibody (Immunoglobulin G) ratio | Through study completion, expected 2 months | The relationship between antibodies to COVID-19 in serum to follicular fluid in female patients going through an egg retrieval |
| Spermatic fluid- Serum Anti COVID-19 antibody (Immunoglobulin G) ratio | Through study completion, expected 2 months | The relationship between antibodies to COVID-19 in serum to spermatic fluid in male patients going through in vitro fertilization treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Follicular fluid Estradiol level (pmol/L) | Through study completion, expected 2 months | Quality assessment of follicular fluid as measured by Estradiol level |
| Follicular fluid Progesterone level (nmol/L) | Through study completion, expected 2 months | Quality assessment of follicular fluid as measured by Progesterone level |
| Follicular fluid Perlecan level (nmol/L) | Through study completion, expected 2 months | Quality assessment of follicular fluid as measured by Perlecan level |
Countries
Israel
Contacts
Primary ContactDaniela Hoffman
Outcome results
None listed